Antibodies

18 May 2023

ImaginAb Advances Two Solid Tumor Radiopharmaceutical Therapy (RPT) Candidates Towards Clinical Development

18 May 2023

ImmunoBrain Checkpoint Doses First Patients in Phase 1b Clinical Trial of IBC-Ab002 for Alzheimer’s Disease

18 May 2023

Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

16 May 2023

Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™

16 May 2023

Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field

15 May 2023

Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic

15 May 2023

BiOneCure Therapeutics and Nanjing Leads Biolabs Join Forces to Develop Innovative Anti-Drug Conjugates (ADCs) for Solid Tumor Treatment

15 May 2023

U.S. Food and Drug Administration Issues Complete Response Letter for Byondis’ [Vic-]Trastuzumab Duocarmazine

15 May 2023

Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease

15 May 2023

Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program

13 May 2023

LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate

12 May 2023

Results of Phase I Clinical Study of Qilu Pharma’s PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & Oncology

10 May 2023

Ultomiris approved in the EU for adults with neuromyelitis optica spectrum disorder (NMOSD)

10 May 2023

Sandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars

10 May 2023

Lassen Therapeutics Announces Oral Presentation of Phase I Data of LASN01, an IL-11 Receptor-Blocking Antibody for Treatment of Pulmonary Fibrosis, at the American Thoracic Society 2023 Annual Meeting

10 May 2023

Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases

10 May 2023

Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)

9 May 2023

Arxx Therapeutics initiates first-in-human trial of AX-202 – a monoclonal antibody under development for fibrotic diseases

9 May 2023

ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease

9 May 2023

FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics

9 May 2023

Biosion Presents Discovery and Development Data at PEGS for its Anti-CD40 Agonistic Antibody

9 May 2023

Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease

9 May 2023

Hummingbird Bioscience to Present Preclinical Proof of Concept for Potentially First-In-Class Antibody Targeting Autoimmune Diseases

9 May 2023

FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)

8 May 2023

Eisai enters into joint development agreement with BlissBio for antibody drug conjugate BB-1701 with option rights for strategic collaboration

5 May 2023

Trellis Bioscience Announces Positive Interim Phase 1 Results for TRL1068, a Novel Native Human Monoclonal Antibody Which Reduces Bacterial Biofilm Burden in Chronic Prosthetic Joint Infections

5 May 2023

Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®

5 May 2023

Tonix Pharmaceuticals Announces IND Clearance for TNX-1500 (anti-CD40L mAb) for the Prevention of Organ Rejection in Patients Receiving a Kidney Transplant

4 May 2023

Convergent Therapeutics Announces $90 Million Series A Financing to Advance the Clinical Development of Radiopharmaceuticals for the Treatment of Prostate Cancer and Other Solid Tumors

3 May 2023

EirGenix’s Second Breast Cancer Biosimilar EG1206A Successfully Reaches Phase 1 Clinical Trial Objectives

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

DLL3-Targeted Immunotherapy Candidates Pipeline Review

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins